lenalidomide sandoz 20 mg
sandoz - københavn - lenalidomid - kapsel, hard - 20 mg
lenalidomide sandoz 25 mg
sandoz - københavn - lenalidomid - kapsel, hard - 25 mg
lenalidomid zentiva 20 mg
zentiva k.s. - lenalidomid - kapsel, hard - 20 mg
lenalidomid zentiva 2.5 mg
zentiva k.s. - lenalidomid - kapsel, hard - 2.5 mg
lenalidomid zentiva 5 mg
zentiva k.s. - lenalidomid - kapsel, hard - 5 mg
lenalidomid zentiva 7.5 mg
zentiva k.s. - lenalidomid - kapsel, hard - 7.5 mg
lenalidomid zentiva 10 mg
zentiva k.s. - lenalidomid - kapsel, hard - 10 mg
lenalidomid zentiva 15 mg
zentiva k.s. - lenalidomid - kapsel, hard - 15 mg
lenalidomid zentiva 25 mg
zentiva k.s. - lenalidomid - kapsel, hard - 25 mg
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.